Ann: Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs, page-3

  1. 1,908 Posts.
    lightbulb Created with Sketch. 374

    "Melbourne, Australia; April 4 and New York, USA; April 3, 2025: Mesoblast (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its products in relation to the U.S. Government’s announcement on tariffs for imported products. Mesoblast believes that its allogeneic cellular products, including Ryoncil® and Revascor®, will not be subject to the tariffs."

    Mesoblast believes....you wouldn't know what to believe with Trump would you????
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$2.52
Change
0.030(1.20%)
Mkt cap ! $3.212B
Open High Low Value Volume
$2.53 $2.55 $2.49 $4.591M 1.824M

Buyers (Bids)

No. Vol. Price($)
24 42413 $2.52
 

Sellers (Offers)

Price($) Vol. No.
$2.53 92996 21
View Market Depth
Last trade - 12.59pm 29/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.